For middle-market stop loss carriers, historical claims experience remains one of the most important inputs for underwriting decisions.
But as pharmacy costs continue to rise and specialty therapies become a larger driver of catastrophic claims, an important question is emerging:
Does the pharmacy claim tell the whole story anymore?
Increasingly, the answer is: not on its own.
Behind many pharmacy claims is a growing web of manufacturer rebates, PBM arrangements, discounts, credits, and regulatory requirements (including federal PBM reform under the Consolidated Appropriations Act of 2026, which requires full rebate pass-through to group health plans beginning in 2029)1 that can significantly influence the true economics of a claim. While employers, PBMs, and manufacturers are adapting to these changes, many stop-loss carriers may not fully understand how they ultimately affect the claims experience being used for underwriting and pricing decisions.
None of this means claims data is less valuable. It means context matters more than ever.
Why This Matters Now
One of the biggest drivers of change is the evolving rebate landscape.
As regulatory requirements continue to reshape how pharmacy rebates are handled, employers are expected to receive a larger share of rebate value directly. In some cases, members may receive some or all the rebate value at the point of sale. Some PBMs have begun adjusting their models in anticipation of these changes, introducing new approaches to pricing, rebate administration, and service fees.
For stop-loss carriers, this raises an important consideration.
If pharmacy dollars are flowing differently than they have historically, could the claims experience being used to evaluate risk become less representative of future economics? The answer will vary by employer, PBM arrangement, and contract structure.
But every carrier should be exploring the underlying question.
A carrier may see a high-cost pharmacy claim without having a complete view of the broader market forces that may influence pharmacy spending over time. Understanding the claim remains essential, but interpreting future risk may also require awareness of the evolving pharmacy environment.
Questions Middle-Market Carriers Should Be Asking
The goal is not for stop-loss carriers to become pharmacy experts. Nor is the objective to create additional underwriting requirements or employer-specific data requests. Rather, it is to ensure carriers consider broader pharmacy market intelligence alongside the information already available to them.
With that in mind, carriers should consider asking:
Do we understand the difference between gross pharmacy claims and net pharmacy economics?
A claim amount alone may not fully reflect the dollars ultimately moving through the system. A broader understanding of how rebates, discounts, and recoveries are evolving across the market can help put claims experience in context.
How are changing rebate and PBM models affecting the employer groups we insure?
PBMs are actively adapting to regulatory and market changes. Understanding those developments may help carriers identify potential impacts on future claims experience.
Are there pharmacy risk factors that may not be evident from claims experience alone?
Claims data remains foundational, but aggregated pharmacy insights and market intelligence may provide additional context regarding the factors driving risk.
Are our policy provisions aligned with today's pharmacy environment?
As rebates, credits, refunds, and other financial arrangements continue to evolve, carriers may benefit from periodically reviewing how those items are addressed contractually.
Are we monitoring the market forces that could change future risk?
Legislation, PBM contracting models, specialty drug pipeline growth, and employer purchasing strategies all have the potential to influence future pharmacy economics and stop loss exposure.
A Different Way to Look at Pharmacy Risk
At Apture, we look at pharmacy-related stop loss risk through three lenses:
Follow the Claim
What drugs, therapies, and conditions are actually driving exposure in your book of business?
Follow the Dollar
How might evolving rebate, manufacturer discount, and PBM structures influence broader pharmacy cost and risk trends?
Follow the Market
What changes are happening upstream that could affect the risk you will be underwriting tomorrow?
This approach ensures underwriting and risk strategies are informed by the forces shaping pharmacy costs today.
The carriers best positioned for the future will likely be those that move beyond evaluating claims alone and focus on understanding the broader forces behind them. As pharmacy continues to transform, underwriting strategies must evolve alongside it.
Carriers do not need to navigate these shifts alone. That is where an experienced partner with both pharmacy and stop loss expertise can help translate market changes into practical underwriting considerations.
1 Consolidated Appropriations Act of 2026, PBM reform provisions; applies to plan years beginning on or after August 3, 2028. See Morgan Lewis summary (JD Supra) and NFP, "Federal PBM Reform Is Finally Law."
What could changing pharmacy economics mean for your stop loss portfolio?
Connect with Apture's stop loss team to find out.